Showing 1 - 17 results of 17 for search 'Kathrin U Jansen', query time: 0.03s
Refine Results
-
1
The role of vaccines in fighting antimicrobial resistance (AMR) by Kathrin U. Jansen, Annaliesa S. Anderson
Published 2018-09-01
Article -
2
-
3
Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches by Judith Absalon, Raphael Simon, David Radley, Peter C. Giardina, Kenneth Koury, Kathrin U. Jansen, Annaliesa S. Anderson
Published 2022-01-01
Article -
4
Performance of a Four-Antigen <i>Staphylococcus aureus</i> Vaccine in Preclinical Models of Invasive <i>S. aureus</i> Disease by Ingrid L. Scully, Yekaterina Timofeyeva, Arthur Illenberger, Peimin Lu, Paul A. Liberator, Kathrin U. Jansen, Annaliesa S. Anderson
Published 2021-01-01
Article -
5
Vaccination strategies for the prevention of meningococcal disease by Scott Vuocolo, Paul Balmer, William C. Gruber, Kathrin U. Jansen, Annaliesa S. Anderson, John L. Perez, Laura J. York
Published 2018-05-01
Article -
6
-
7
A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States by David Fitz-Patrick, Mariano Young Jr, Daniel A. Scott, Ingrid L. Scully, Gary Baugher, Yahong Peng, Kathrin U. Jansen, William Gruber, Wendy Watson
Published 2021-07-01
Article -
8
Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults by Megumi Inoue, Takuma Yonemura, James Baber, Yasuko Shoji, Masakazu Aizawa, David Cooper, Joseph Eiden, William C. Gruber, Kathrin U. Jansen, Annaliesa S. Anderson, Alejandra Gurtman
Published 2018-11-01
Article -
9
A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age by Brandon Essink, James Peterson, Kari Yacisin, Himal Lal, Sarah Mirza, Xia Xu, Ingrid L. Scully, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Wendy Watson
Published 2021-08-01
Article -
10
Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease by Charu Sabharwal, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Todd J. Belanger, Bradford D. Gessner, Luis Jodar, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson
Published 2022-11-01
Article -
11
-
12
-
13
Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a r... by Allison R. Thompson, Nicola P. Klein, H. Jackson Downey, Scott Patterson, Vani Sundaraiyer, Wendy Watson, Keri Clarke, Kathrin U. Jansen, Shite Sebastian, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma
Published 2019-02-01
Article -
14
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine by John L. Perez, Judith Absalon, Johannes Beeslaar, Paul Balmer, Kathrin U. Jansen, Thomas R. Jones, Shannon Harris, Laura J. York, Qin Jiang, David Radley, Annaliesa S. Anderson, Graham Crowther, Joseph J. Eiden
Published 2018-06-01
Article -
15
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection by Chaitanya Kurhade, Jing Zou, Hongjie Xia, Mingru Liu, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Ugur Sahin, Kathrin U. Jansen, Ping Ren, Xuping Xie, Kena A. Swanson, Pei-Yong Shi
Published 2022-12-01
Article -
16
Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial by Michael W. Simon, Regine Bataille, Nicole S. Caldwell, Bradford D. Gessner, Luis Jodar, Erik Lamberth, Yahong Peng, Daniel A. Scott, Lanyu Lei, Peter C. Giardina, William C. Gruber, Kathrin U. Jansen, Allison Thompson, Wendy Watson
Published 2023-08-01
Article -
17
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants by Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver, Kena A. Swanson, Hui Cai, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Ugur Sahin, Xuping Xie, Philip R. Dormitzer, Pei-Yong Shi
Published 2022-04-01
Article